

# Gemini Stock Analysis Report

---

Okay, I will analyze the ZYDUSLIFE.NS report following your specified steps.

## Step 1: Audit the Data

- **Data Present:**
  - Daily Price Chart (3 Year)
  - Long-term and Short-term Fundamental Analysis
  - Relative Strength Analysis (RS Ratios and Trends)
  - EMA Crossover Summary (20, 50, 200)
  - Bollinger Bands Summary (20, 2)
  - Supertrend Summary
  - MACD Summary (12, 26, 9)
  - Volatility Squeeze Summary
  - RSI-Volume Summary
- **Data Missing:**
  - Volume Trend
  - Weekly charts for longer-term perspective
  - Fibonacci levels or other advanced pattern analysis
- **Confidence Level:** Medium. The report provides a solid overview of price action, relative strength, and key indicators. However, the lack of weekly charts and volume trend metrics weakens my conviction for a longer-term (1-4 month) positional trade.

## Step 2: Analyze the Setup

- **Price Structure:** The 3-year daily chart shows a general uptrend until mid-2024, followed by a consolidation phase with fluctuations. The price is currently around INR 919.60.
- **Trend Direction:** The EMA Crossover Summary indicates a "Strong **Downtrend**" as the price is below the EMA 20, EMA 50, and EMA 200. The Supertrend indicator also confirms a "**Downtrend** (Sell)" signal.
- **Momentum:** The MACD Summary indicates a "**Bullish**" trend with "Strengthening" momentum. This is a potential divergence from the overall downtrend, which needs confirmation. The RSI is at 40.84, not oversold, leaving room for further downside.
- **Relative Strength:** The classification is neutral, and while emerging RS is confirmed, the performance is not improving.
- **Bollinger Bands:** Current price is in the Lower Half which indicates weakness.

## Step 3: Formulate the Recommendation

No, I would not recommend entering a long position in ZYDUSLIFE.NS at this time.

### Reasoning:

The overall trend is bearish, confirmed by both EMA crossovers and the Supertrend indicator. Although the MACD shows bullish momentum, this is not strong enough to counter the prevailing downward trend. The lack of confirmation on a strong move out of the lower band is concerning. Additionally, the "Strong **Downtrend**" is a strong bearish signal.

### Conditional Plan:

- **Condition to Buy:** A clear and sustained breakout above the EMA 50 (currently at INR 947.03) and the Supertrend level (INR 951.38) would signal a potential trend reversal. Confirmation would be a bullish crossover on MACD.
- **Entry Price:** INR 952 (after a confirmed close above EMA 50 and Supertrend level)

# Gemini Stock Analysis Report

- **Stop Loss:** INR 915 (below recent lows)
- **Take Profit:** INR 1015 (approximately 5% potential upside)

**Disclaimer:** This analysis is based on the provided report and my interpretation of the data. It is for informational purposes only and does not constitute financial advice. Always conduct thorough research and consider your risk tolerance before making any investment decisions.

## News & Analyst Targets

Okay, I will act as a stock research analyst and provide you with the latest information on ZYDUSLIFE. I will search for news, brokerage ratings, and analyst targets, and present the target information in a Markdown table.

Here's a summary of the latest news and information on ZYDUSLIFE, as of December 20, 2025:

### 1. Latest News for ZYDUSLIFE This Week:

- **Cancer-Risk Assessment Diagnostic Tests:** Zydus Lifesciences has signed an agreement with Myriad Genetics to launch cancer-risk assessment diagnostic tests in India. (December 19, 2025)
- **USFDA Approval:** Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg.
- **USFDA Approval:** Zydus receives final approval from USFDA for Droximef Fumarate Delayed-Release Capsules, 231 mg.
- **China Approval:** Zydus receives approval from China's NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg.
- **Financial Performance:** In Q2 FY26, Zydus Lifesciences' consolidated revenue reached Rs. 61.2 billion, driven by strong growth in US and branded formulations.
- **Orphan Drug Designation:** Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of beta-thalassemia.
- **Amplitude Surgical Robotic System:** Zydus' Amplitude receives CE mark for its robotic surgical system "Andy".

### 2. Brokerage Upgrades and Downgrades for ZYDUSLIFE:

- Jefferies analysts lowered the price target on Zydus Lifesciences to INR1,150.00 (from INR1,350.00) while maintaining a Buy rating.
- JPMorgan analysts lowered the price target on Zydus Lifesciences to INR1,000.00 (from INR1,140.00) while maintaining a Neutral rating.
- HSBC analyst Damayanti Kerai raised the price target on Zydus Lifesciences to INR965. 00 (from INR920.00) while maintaining a Hold rating

### 3. Other News Impacting ZYDUSLIFE:

- **Plans to Raise Funds:** Zydus Lifesciences plans to raise Rs 5,000 crore via share sales to reduce debt and boost future expansion.
- **Acquisitions:** Strategic acquisitions, such as Comfort Click Limited and Amplitude Surgical, are enhancing its market presence in consumer wellness and orthopedics.
- **Challenges:** Declining sales of Revlimid and concerns over US revenue performance

### 4. Latest Targets from Analysts:

Here's a table summarizing the latest analyst targets for ZYDUSLIFE:

# Gemini Stock Analysis Report

---

Metric	Value (INR)
Average 1-Year Price Target	1,039.49
Low Forecast	858.5
High Forecast	1,376.55
Average Target Price (TipRanks)	965.00

**Disclaimer:** Please note that these are just analyst estimates and should not be taken as financial advice. Consider consulting a financial advisor before making any investment decisions.


# Stock Detailed Analysis Report

**ZYDUSLIFE.NS**

Current Price: ₹919.60

Generated: 2025-12-20 20:45

# ZYDUSLIFE.NS - 3 Year Daily Price Chart



# Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	18.68%	15.04%
Net Income	Yes	Yes	17.26%	0.28%
ROE	No	Yes	-2.93%	-10.55%
EPS	Yes	Yes	17.91%	0.86%

# Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	2.81%	2.59%
Net Income	Yes	25.27%	4.04%
ROE	Yes	17.08%	17.08%
EPS	No	12.25%	-11.77%

# ZYDUSLIFE.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Neutral</b>
RS Score:	46.3/100

:

## == RS RATIOS ==:

1M RS:	<b>0.988 [Neutral]</b>
3M RS:	<b>0.880 [Neutral]</b>
6M RS:	<b>0.906 [Neutral]</b>
1Y RS:	<b>0.923 [Neutral]</b>

:

## == TURNAROUND ANALYSIS ==:

Turnaround Status:	<b>Not Detected</b>
--------------------	---------------------


:

## SIGNAL CRITERIA::


✓ Emerging RS:	1M (0.988) > 3M (0.880)
✓ Medium-term Lagging:	6M=0.906, 1Y=0.923 ( $\leq 1.0$ )
✗ Performance Improving:	<b>Not improving</b>

Relative Strength Analysis: ZYDUSLIFE.NS vs ^CNXPHARMA  
Classification: Neutral


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



## ZYDUSLIFE.NS - EMA Crossover Summary

EMA 20:	928.03
EMA 50:	947.03
EMA 200:	961.76
Trend Status:	<b>Strong Downtrend</b>


ZYDUSLIFE.NS EMA Crossover Analysis



## ZYDUSLIFE.NS - Bollinger Bands Summary

<b>Current Price:</b>	919.60
<b>Upper Band:</b>	946.48
<b>Middle Band (SMA 20):</b>	928.21
<b>Lower Band:</b>	909.94
<b>%B:</b>	0.2644
<b>Band Width:</b>	0.0394
<b>Status:</b>	Lower Half
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<b>Buy Signal at 2025-11-07 00:00:00</b>
<b>Recent Signal 2:</b>	<b>Buy Signal at 2025-12-18 00:00:00</b>


ZYDUSLIFE.NS Bollinger Bands (20, 2) Analysis



## ZYDUSLIFE.NS - Supertrend Summary

Status:	<b>DOWNTREND (Sell)</b>
Supertrend Value:	951.38
Signal Identified On:	2025-09-26


Supertrend Analysis for ZYDUSLIFE.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## ZYDUSLIFE.NS - MACD Summary

MACD Line:	-9.54
Signal Line:	-10.00
Histogram:	0.45
Trend:	<b>Bullish</b>
Momentum:	<b>Strengthening</b>
Signal:	None
Divergences Detected:	1
└ <b>Bullish Divergence:</b>	Date: 2025-12-18 00:00:00, Price: 913.65

ZYDUSLIFE.NS Price






ZYDUSLIFE.NS MACD (12, 26, 9)



# ZYDUSLIFE.NS - Volatility Squeeze Summary

BB Width:	0.0394
ATR:	12.8072
Total Signals:	28
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-15 00:00:00 (Price: 92.1)
Signal 2:	BB Squeeze + ATR Contraction at 2025-12-16 00:00:00 (Price: 91.4)
Signal 3:	BB Squeeze + ATR Contraction at 2025-12-17 00:00:00 (Price: 91.8)
Signal 4:	BB Squeeze + ATR Contraction at 2025-12-18 00:00:00 (Price: 91.3)
Signal 5:	BB Squeeze + ATR Contraction at 2025-12-19 00:00:00 (Price: 91.9)

# ZYDUSLIFE.NS - Volatility Squeeze Analysis



## ZYDUSLIFE.NS - RSI-Volume Summary

<b>Current RSI:</b>	40.84
<b>Current Volume:</b>	799834
<b>Volume MA 20:</b>	945614
<b>Bullish Divergences:</b>	6
<b>Bearish Divergences:</b>	3
<b>Bullish Div 1:</b>	Date: 2025-11-21 00:00:00, Price: 924.30
<b>Bullish Div 2:</b>	Date: 2025-12-18 00:00:00, Price: 913.65
<b>Bearish Div 1:</b>	Date: 2025-07-01 00:00:00, Price: 1002.50
<b>Bearish Div 2:</b>	Date: 2025-09-18 00:00:00, Price: 1047.85

# ZYDUSLIFE.NS RSI-Volume Divergence Analysis

